Point: Major adverse cardiovascular events and anti-IL 12/23 agents - 16/01/14
Funding sources: None. |
|
Disclosure: Dr Tzellos has been reimbursed for travel expenses and hotel accommodation to attend dermatological congresses by Janssen-Cilag, which produces ustekinumab (Stelara), by MSD, which produces infliximab (Remicade), and by Novartis. Dr Zouboulis has been reimbursed for travel expenses and hotel accommodation and has received honorarium for participating and lecturing at the Advisory Board for hidradenitis suppurativa of AbbVie, which produces adalimumab (Humira). He has also participated and continues to participate at clinical studies on the treatment of hidradenitis suppurativa with adalimumab sponsored by AbbVie. Dr Trigoni has participated at clinical trials for chronic plaque psoriasis sponsored by Abbott, Janssen-Cilag, Pfizer, and MSD. Dr Kyrgidis declares no conflict of interest. |
Vol 70 - N° 2
P. 380-381 - février 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?